ArticleOncology letters2025
Short‑term efficacy assessment of brigatinib for the treatment of neurofibromatosis type 2: A retrospective study.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Small-Molecule Drugs in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofibromatosis type 2 (NF2) is a genetic disorder caused by mutations in the NF2 tumor suppressor gene. This disease causes the growth of multiple schwannomas and meningiomas. There are currently no Food and Drug Administration-approved treatments for these malignancies. Due to their continuous development, these tumors cause a high rate of morbidity and mortality. The aim of the present study was to observe the short-term efficacy of brigatinib in treating NF2. Patients diagnosed with NF2 at The First Medical Center of Chinese PLA General Hospital (Beijing, China) between June 2021 and April 2024 were retrospectively enrolled and treated with 90 mg oral brigatinib once daily, with changes in the size of meningiomas and vestibular schwannomas, as well as hearing, emotional state and pain, measured before and after treatment. Adverse reactions to medication administration were also seen and documented. Changes in markers before and after therapy were investigated using repeated-measures ANOVA. Patients were stratified into two age groups (<18 and ≥18 years), with disease progression evaluated by longitudinal changes in meningioma maximal diameter on magnetic resonance imaging. The log-rank test was used to determine the difference in time between drug delivery and illness development. A total of 12 patients were enrolled. After 12 months of oral brigatinib therapy, the meningioma volume significantly decreased (P<0.05) at both the 6 and 12th month. There was a significant difference in time to illness development between individuals aged <18 and ≥18 years (P=0.049). The symptom checklist-90 and visual analogue scale scores were considerably reduced at 6 and 12 months (P<0.05). However, no significant improvement was seen in acoustic neuroma volume or the mean hearing threshold (both P>0.05). In conclusion, brigatinib may relieve meningiomas and pain and improve emotional well-being in patients with NF2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.